IMPT-314 in Aggressive B-Cell Non-Hodgkin Lymphoma

What is the Purpose of this Study?

The purpose of this study is to evaluate experimental gene-modified immune cells called IMPT-314 for the treatment of lymphomas that have either come back after treatment or have stopped responding to treatment. IMPT-314 is a type of drug called a chimeric antigen receptor T cell, also known as a CAR T cell. Researchers aim to examine the safety and side effects of IMPT-314, determine which dosages are safe for people to take, and evaluate how well the study drug destroys cancer cells. A virus will be used to introduce a gene that creates a protein called a chimeric antigen receptor (CAR) on the surface of the T cells, a type of white blood cell that fights infection and eliminates cancer cells. The study will collect and modify some of the patient’s own white blood cells and give them back to the patient in the hope that these cells can then identify and possibly kill cancerous cells.


Eligibility

  • 1. Age 18 years or older
  • 2. Willing and able to provide written informed consent
  • 3. Histologically confirmed aggressive NHL, including the following types defined by the World Health Organization (WHO 2017):
Show more

Where can I participate?

CS Cancer at Cedars-Sinai Medical Center : Amy Oppenheim

More about this Clinical Trial

What is the full name of this clinical trial?

MPCT-012L: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor T Cell Therapy in Participants with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Study Details
Disease Type/Condition

Non-Hodgkin's Lymphoma

Principal Investigator

Merchant, Akil

Co-Investigators

David Oveisi, Hannah Lee, Joshua Sasine, Justin Darrah, Noah Merin, Robert Vescio, Ronald Paquette

Age Group

Adult

Phase

I/II

IRB Number

STUDY00002922

ClinicalTrials.gov ID

NCT05826535

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Amy Oppenheim

Phone
+1 310-423-3713
Email
amy.oppenheim@cshs.org
Study Detail
Disease Type/Condition

Non-Hodgkin's Lymphoma

Principal Investigator

Merchant, Akil

Age Group

Adult

Phase

I/II

IRB Number

MPCT-012L

ClinicalTrials.gov ID

NCT05826535

Key Eligibility
ClinicalTrials.gov

Contact
Name

Amy Oppenheim

Phone
+1 310-423-3713
Email
amy.oppenheim@cshs.org